Carrillokramer5285

ant ADT for RP patients.The addition of a fourth year to the hospital pharmacy residency program has allowed trainees to rotate through various inpatient clinical units where they can, under the supervision of a specialist pharmacist, work shoulder to shoulder with other healthcare providers to ensure that patients receive the care they need. In addition to sharing their pharmacotherapeutic and pharmacokinetic knowledge (among others) with their colleagues, hospital pharmacists can and should contribute with their expertise in the areas of drug evaluation, selection and positioning. As no other healthcare professional masters like a pharmacist the intricacies of treatment efficacy or effectiveness, or of therapeutic safety, conveying this knowledge is yet another of the many clinical activities a hospital pharmacist must perform as a member of a multidisciplinary team, while assisting fellow-team members in deciding what medications are best suited to each patient. Both the public authorities and the pharmaceutical profession as a whole should make sure the pharmacist's role is rightfully valued and given the recognition it deserves.

To present a new dexamethasone mouthwash formulationand analyze its effectiveness and safety among patients receiving stomatitis-producing antineoplastic agents.

Prospective observational study conducted in a university hospitalbetween March 2017 and November 2019. Consecutive patientsstarting everolimus were enrolled. Patients were instructed to rinse dexamethasonemouthwash formulation twice daily until discontinuation ofeverolimus. A second cohort of patients with existing stomatitis inducedby high probability of producing stomatitis chemotherapy therapies wasalso recruited to assess treatment effectiveness. Effectiveness and safety ofdexamethasone mouthwash formulation was assessed.

Dexamethasone mouthwash formulation was prescribed in ninepatients as prophylaxis. Six patients were diagnosed with breast cancer,two with neuroendocrine tumor and one with renal cell carcinoma. Fourpatients developed mild stomatitis (grade 1-2) and three patients discontinuedeverolimus due to other treatment-related adverse events. In addition,dexamethasone mouthwash formulation was prescribed as treatment infive patients with existing stomatitis. All patients achieved a significantreduction in the severity of stomatitis after starting the dexamethasone mouthwash formulation. In both cohorts, dexamethasone mouthwash formulationwas well tolerated and neither dose reduction nor discontinuationrelated to stomatitis was required.

Dexamethasone mouthwash formulation could be consideredas a suitable alternative for stomatitis management.

Dexamethasone mouthwash formulation could be considered as a suitable alternative for stomatitis management.

To report on the results obtained from the 2019 SEFH NationalSurvey regarding the service portfolio, care activities, training programsand research work of Spanish hospital pharmacy departments.

In March 2019, SEFH designed and distributed a questionnairecontaining 77 questions grouped into 8 domains to its 368 affiliatedhospital pharmacy departments. The questionnaire included an additionalsection on the activities carried out in 2017 and 2018.

The overall response rate was 54.3%. Sixty-nine percent ofhospitals were public and 75% were general hospitals. A total of 88.6%of hospital pharmacy departments provided pharmaceutical care toinpatients, whereas 77.5% and 65% treated outpatients and ambulatorypatients, respectively. Sterile formulations were prepared by 70.6%of pharmacy departments, while 12% measured drug levels in bodilyfluids; 76.9% of hospitals with more than 1,000 beds prepared pharmacokineticreports. In 2018, hospital pharmacies provided for a meanof 929 patients a month and 2,680 a year. main activities performed in Spanish hospital pharmacies,while there is still considerable room for improvement in the area of clinicalpharmacokinetics. Pharmacy departments are generally committed totraining as a key activity, while scientific output is still limited despite theincrease in the number of PhD pharmacist.

Care of out-patients and medication compounding are increasingly the main activities performed in Spanish hospital pharmacies, while there is still considerable room for improvement in the area of clinical pharmacokinetics. Pharmacy departments are generally committed to training as a key activity, while scientific output is still limited despite the increase in the number of PhD pharmacist.

Remdesivir has not shown survival benefit for patients withsevere COVID-19. However, subgroup analysis of ACTT-1 Study Groupshowed an apparent reduction in mortality for patients who requirednon‑high-flow oxygen. Presentation of SOLIDARITY study results wereassociated by a meta-analysis combining mortality results by subsets romrandomized clinical trials. The aim is a methodological assessment ofreliability and clinical applicability about findings by subgroups on theeffect of remdesivir on mortality in patients with COVID-19.

A validated tool was used to evaluate the findings of subgroupanalyses in randomized clinical trials, including meta-analysis atached toSOLIDARITY study. It is structured in preliminary questions to reject subsetanalyses without relevant minimum conditions, and a specific checklist.The latter considers certain criteria statistical association, which encompassedp of interaction, prespecification of subgroups, sample size, numberof factors analyzed, and overall study result; biologicad interpretation of subgroup analysis suggestedtoo much uncertainty in hypothesis about remdesivir could reducemortality in patients with severe COVID-19 who required non-high- flowoxygen. It was probably a random finding. Therefore, a randomized clinicaltrial about effect of remdesivir in mortality in patients with COVID‑19and non-high-flow oxygen is essential.

This structured interpretation of subgroup analysis suggested too much uncertainty in hypothesis about remdesivir could reduce mortality in patients with severe COVID-19 who required non-high- flow oxygen. It was probably a random finding. Therefore, a randomized clinical trial about effect of remdesivir in mortality in patients with COVID‑19 and non-high-flow oxygen is essential.

To evaluate the efficacy and safety of anti-PD-1 and anti-PD-L1immunotherapy agents as monotherapy in patients with non-small cell lungcancer.

This was a four-year retrospective observational study thatincluded all patients with non-small cell lung cancer treated with nivolumab,pembrolizumab, and atezolizumab in a third level hospital.Demographic, clinical (ECOG status, stage, PD-L1 expression level),therapeutic (drug, start date, line of treatment and number of cycles),efficacy (date and status at the end of follow-up) and toxicity variableswere collected. Data was extracted from the patient's electronic medicalrecord. Overall survival and progression-free survival rates for differentmonitoring times were calculated.

The study included 80 patients, 35 on nivolumab, 32 on pembrolizumaband 13 on atezolizumab. The median overall survival was notachieved. Overall survival at 6, 12, 18 and 49 months in patients treatedwith nivolumab was 79.7%, 74.0%, 65.8% and 65.8%, respectively.Median progression-free surstudies. Further studies are requiredwith larger sample sizes and longer follow-up times to confirm thesefindings.

Subjects showed a trend toward stabilization and chronification of the disease. A positive and considerable survival rate was observed, as compared with previous studies. Further studies are required with larger sample sizes and longer follow-up times to confirm these findings.

To determine persistence of treatment with secukinumabacross its different indications.

This is a retrospective descriptive observational study includingadult patients treated with secukinumab in its different indications from thedrug's introduction in November 2015 to October 2019. The variablesincluded were sex; age; diagnosis; initiation date; line of treatment; numberof patients who discontinued treatment and reason for discontinuation;overall persistence at 12 months; distribution of patients; and persistenceaccording to indication, line of treatment and reason for suspension.

One-hundred forty-three patients were started on secukinumab,but only patients who had been in treatment at least 12 months before theend of the study were included. Mean patient age was 49.8 years (±12.6);52.9% were men. Fifty-six patients (53.8%) had discontinued treatment bythe end of the study, with a mean duration of treatment of 12.7 months(±10.2). Tebipenem Pivoxil in vivo The other patients (n = 48) continued with their therapy. Meanduration o3.5 months (±0.5) if they presented with primary treatment failure, and 8.3 months (±2.5) in those with secondary treatment failure.

Our data show slightly higher persistence levels in patientswith psoriasis and lower discontinuation rates in those without previousexposure to biological therapy. Long-term studies are needed to confirmthese findings and to gain a better understanding of the factors that caninfluence persistence of secukinumab.

Our data show slightly higher persistence levels in patients with psoriasis and lower discontinuation rates in those without previous exposure to biological therapy. Long-term studies are needed to confirm these findings and to gain a better understanding of the factors that can influence persistence of secukinumab.

To assess the general healthcare impact of a Biological TherapiesCommitee (immune-mediated inflammatory diseases) through prescriptionhabits, pre-biological studies and immunization.

A quasi-experimental study was conducted on all naïvepatients of legal age who started treatment with a biological agent for animmune- mediated inflammatory disease the year before and the year afterthe creation of the Biological Therapies Committee.

A total of 31 patients treated in 2016 and 40 patients treated in2018 were included. Prescriptions of tumor necrosis factor alpha inhibitordrugs decreased in 2018 (from 80.6% to 45.0%, p < 0.05), while prescriptionsof interleukin 12/23 inhibitors increased (from 12.9% to 35.0%,p < 0.05). Tuberculosis screening was statistically different between thetwo periods the number of interferon gamma release assays performedwas higher in 2018 (from 9.7% to 80.0%, p < 0.01) and the proportionof patients who successfully underwent chemoprophylaxis was higher in2018 (from 36.4% to 81.8%, p < 0.05). The proportion of tests requestedfor the study of viral pathologies and the number of vaccines administeredwere also higher in 2018.

The development of a specific Biological Therapies Committeeallows healthcare improvements, contributing to a deeper understandingof the medications and to preventing the infection-related adverseevents. It would therefore seem advisable to develop specialized committeesakin to the Biological Therapies Committee in other domains.

The development of a specific Biological Therapies Committee allows healthcare improvements, contributing to a deeper understanding of the medications and to preventing the infection-related adverse events. It would therefore seem advisable to develop specialized committees akin to the Biological Therapies Committee in other domains.